Dr Lal Path Labs Share Price Today (LALPATHLAB)
TODAY IN ONE LINE
LALPATHLAB fell 1.0% on light volume, lagging Nifty's 0.0% move, supported by recent strong earnings.
With a market cap of ₹30,607.3 Cr., it trades at a P/E of 56.46. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Dr Lal Path Labs flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 28.0% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 22.3%
- ●Healthy Operating MarginsOPM is structurally strong at 28.4%
- ●High Promoter HoldingPromoters hold 53.2% skin-in-the-game
- ●Steady Dividend YieldReliable 1.01% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 15.4% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 54.0x
- ●Promoter SellingPromoter holding decreased by 0.58% QoQ
- ●Rising Receivables vs SalesReceivables grew 12.5% outpacing sales growth of 10.5%
Latest Dr Lal Path Labs News
What changed recently?
Recent events, corporate actions, and announcements.
Dr. Lal Path Labs Ltd. valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Dr. Lal Path Labs Ltd., framed against the sector median so the premium or discount is obvious at a glance.
Dr. Lal Path Labs Ltd. trades at a P/E of 56.46× and P/B of 12.20×, against the Healthcare sector median P/E of 45.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Dr. Lal Path Labs Ltd. technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Dr. Lal Path Labs Ltd. — derived from the live tape, not yesterday's close.
Dr. Lal Path Labs Ltd. last traded at ₹1,809 with an intraday range of ₹1,809–₹1,834.2 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1809.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1876.20 | +67.20 | +3.71% |
| R3 | 1851.00 | +42.00 | +2.32% |
| R2 | 1842.60 | +33.60 | +1.86% |
| R1 | 1825.80 | +16.80 | +0.93% |
| PIVOT | 1817.40 | 8.40 | 0.46% |
| CURRENT | 1809.00 | — | — |
| S1 | 1800.60 | -8.40 | -0.46% |
| S2 | 1792.20 | -16.80 | -0.93% |
| S3 | 1775.40 | -33.60 | -1.86% |
| S4 | 1750.20 | -58.80 | -3.25% |
LALPATHLAB is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1811.1–₹1834
Trading Inside opening range
Dr. Lal Path Labs Ltd. financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Dr. Lal Path Labs Ltd. — consolidated or standalone — with margins, YoY growth and key ratios inline.
Dr. Lal Path Labs Ltd. reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹30,607.3 Cr. and reported EPS of ₹30.26.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,461 | 2,763 ▲ 12.2% |
| Sales Growth YoY %Derived | 10.55% | 12.25% |
| Other Income | 93 | 101 ▲ 8.5% |
| Total Income | 2,555 | 2,864 ▲ 12.1% |
| 482 | 535 ▲ 11.0% | |
| Gross ProfitDerived | 1,980 | 2,228 ▲ 12.5% |
| Gross Margin %Derived | 80.44% | 80.65% |
| 1,284 | 1,446 ▲ 12.6% | |
| EBITDA (Operating Profit)Derived | 696 | 783 ▲ 12.5% |
| OPM %Derived | 28.26% | 28.32% |
| 164 | 155 ▼ 5.9% | |
| Profit Before Tax (PBT) | 625 | 669 ▲ 7.1% |
| 133 | 159 ▲ 20.2% | |
| Effective Tax %Derived | 21.21% | 23.81% |
| Total Profit for Period | 492 | 510 ▲ 3.6% |
| Less: Non-controlling Interests | 5 | 5 ▼ 2.0% |
| Net Profit (Owner's PAT)Derived | 487 | 505 ▲ 3.6% |
| Net Profit Margin %Derived | 19.79% | 18.27% |
| PAT Growth YoY %Derived | 36.18% | 3.63% |
| Earnings Per Share (EPS ₹) | 29.14 | 30.13 ▲ 3.4% |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.2% |
| Other Comprehensive Income (Net of Tax) | -4 | 5 ▲ 244.4% |
| Total Expenses (incl. D&A & Interest) | 1,930 | 2,195 ▲ 13.7% |
| Material Cost % of RevenueDerived | 19.56% | 19.35% |
| Employee Cost % of RevenueDerived | 19.60% | 18.22% |
| Other Cost % of RevenueDerived | 32.58% | 34.11% |
| Interest Coverage (x)Derived | 24.83x | 27.22x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,057 | 1,203 ▲ 13.9% | 1,330 ▲ 10.6% | 1,581 ▲ 18.9% | 2,087 ▲ 32.0% | 2,017 ▼ 3.4% | 2,227 ▲ 10.4% | 2,461 ▲ 10.5% | 2,763 ▲ 12.2% | |
| Sales Growth YoY %Derived | — | 13.86% | 10.55% | 18.86% | 32.01% | -3.38% | 10.40% | 10.55% | 12.25% | |
| Other Income | 31 | 46 ▲ 47.4% | 55 ▲ 19.6% | 51 ▼ 6.7% | 53 ▲ 2.3% | 42 ▼ 20.6% | 69 ▲ 65.9% | 93 ▲ 35.0% | 101 ▲ 8.5% | |
| Total Income | 1,088 | 1,249 ▲ 14.8% | 1,385 ▲ 10.9% | 1,633 ▲ 17.8% | 2,140 ▲ 31.1% | 2,059 ▼ 3.8% | 2,296 ▲ 11.5% | 2,555 ▲ 11.3% | 2,864 ▲ 12.1% | |
226 | 262 ▲ 16.1% | 299 ▲ 13.8% | 397 ▲ 33.0% | 502 ▲ 26.4% | 447 ▼ 11.0% | 451 ▲ 0.9% | 482 ▲ 6.7% | 535 ▲ 11.0% | ||
| Gross ProfitDerived | 831 | 941 ▲ 13.3% | 1,032 ▲ 9.6% | 1,184 ▲ 14.8% | 1,585 ▲ 33.9% | 1,570 ▼ 1.0% | 1,775 ▲ 13.1% | 1,980 ▲ 11.5% | 2,228 ▲ 12.5% | |
| Gross Margin %Derived | 78.62% | 78.20% | 77.55% | 74.88% | 75.94% | 77.83% | 79.73% | 80.44% | 80.65% | |
567 | 647 ▲ 14.2% | 688 ▲ 6.3% | 748 ▲ 8.7% | 1,024 ▲ 37.0% | 1,080 ▲ 5.4% | 1,166 ▲ 8.0% | 1,284 ▲ 10.2% | 1,446 ▲ 12.6% | ||
| EBITDA (Operating Profit)Derived | 264 | 294 ▲ 11.2% | 344 ▲ 17.0% | 436 ▲ 27.0% | 561 ▲ 28.5% | 490 ▼ 12.6% | 609 ▲ 24.4% | 696 ▲ 14.1% | 783 ▲ 12.5% | |
| OPM %Derived | 24.98% | 24.40% | 25.83% | 27.59% | 26.86% | 24.29% | 27.36% | 28.26% | 28.32% | |
34 | 39 ▲ 15.0% | 88 ▲ 125.9% | 93 ▲ 5.8% | 138 ▲ 48.4% | 188 ▲ 35.7% | 173 ▼ 7.8% | 164 ▼ 5.1% | 155 ▼ 5.9% | ||
| Profit Before Tax (PBT) | 261 | 301 ▲ 15.0% | 311 ▲ 3.3% | 394 ▲ 27.0% | 475 ▲ 20.4% | 344 ▼ 27.6% | 506 ▲ 47.0% | 625 ▲ 23.6% | 669 ▲ 7.1% | |
90 | 100 ▲ 11.8% | 83 ▼ 17.2% | 98 ▲ 18.1% | 125 ▲ 27.3% | 103 ▼ 17.5% | 143 ▲ 39.3% | 133 ▼ 7.5% | 159 ▲ 20.2% | ||
| Effective Tax %Derived | 34.25% | 33.30% | 26.70% | 24.82% | 26.24% | 29.89% | 28.33% | 21.21% | 23.81% | |
| Total Profit for Period | 172 | 201 ▲ 16.7% | 228 ▲ 13.5% | 297 ▲ 30.3% | 350 ▲ 18.1% | 241 ▼ 31.2% | 362 ▲ 50.3% | 492 ▲ 35.9% | 510 ▲ 3.6% | |
| Less: Non-controlling Interests | 1 | 1 ▲ 30.0% | 2 ▲ 30.8% | 5 ▲ 188.2% | 6 ▲ 12.2% | 2 ▼ 60.0% | 5 ▲ 109.1% | 5 ▲ 10.9% | 5 ▼ 2.0% | |
| Net Profit (Owner's PAT)Derived | 171 | 199 ▲ 16.6% | 226 ▲ 13.4% | 292 ▲ 29.1% | 345 ▲ 18.2% | 239 ▼ 30.7% | 358 ▲ 49.7% | 487 ▲ 36.2% | 505 ▲ 3.6% | |
| Net Profit Margin %Derived | 16.16% | 16.55% | 16.98% | 18.44% | 16.52% | 11.84% | 16.06% | 19.79% | 18.27% | |
| PAT Growth YoY %Derived | — | 16.63% | 13.40% | 29.08% | 18.24% | -30.71% | 49.73% | 36.18% | 3.63% | |
| Earnings Per Share (EPS ₹) | 10.25 | 11.95 ▲ 16.6% | 13.55 ▲ 13.4% | 17.49 ▲ 29.1% | 20.69 ▲ 18.3% | 14.33 ▼ 30.7% | 21.42 ▲ 49.5% | 29.14 ▲ 36.0% | 30.13 ▲ 3.4% | |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.1% | 17 ▲ 0.1% | 17 ▲ 0.2% | |
| Other Comprehensive Income (Net of Tax) | 0 | -2 ▼ 600.0% | -1 ▲ 45.0% | -1 ▲ 27.3% | -1 ▼ 62.5% | 2 ▲ 223.1% | -1 ▼ 137.5% | -4 ▼ 500.0% | 5 ▲ 244.4% | |
| Total Expenses (incl. D&A & Interest) | 827 | 949 ▲ 14.8% | 1,075 ▲ 13.3% | 1,238 ▲ 15.2% | 1,665 ▲ 34.5% | 1,715 ▲ 3.0% | 1,790 ▲ 4.4% | 1,930 ▲ 7.8% | 2,195 ▲ 13.7% | |
| Material Cost % of RevenueDerived | 21.38% | 21.80% | 22.45% | 25.12% | 24.06% | 22.17% | 20.27% | 19.56% | 19.35% | |
| Employee Cost % of RevenueDerived | 17.10% | 17.31% | 18.24% | 17.31% | 17.48% | 18.67% | 19.06% | 19.60% | 18.22% | |
| Other Cost % of RevenueDerived | 36.54% | 36.49% | 33.49% | 29.98% | 31.59% | 34.87% | 33.30% | 32.58% | 34.11% | |
| Interest Coverage (x)Derived | 288.63x | 319.25x | 17.70x | 22.44x | 14.99x | 9.06x | 15.84x | 24.83x | 27.22x |
Dr Lal Path Labs segment analysis : revenue and profit mix.
Disclosed business segments at Dr Lal Path Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Dr Lal Path Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Dr. Lal Path Labs Ltd..
Our AI distills the core fundamental drivers supporting Dr. Lal Path Labs Ltd., the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Dr. Lal Path Labs Ltd.'s investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust ROE 22.30% and ROCE 28.00% demonstrate efficient capital deployment.
Operating margin 22.77% TTM reflects strong pricing power and operational efficiency.
Minimal financial leverage with debt-to-equity ratio 0.0008, virtually debt-free.
Promoter holding 53.21% signals stable governance and long-term commitment.
Market leader with ₹0.31 LCr market cap commanding India's largest diagnostic network.
Key Risks.
Latest quarterly EPS declined 15.2% YoY despite revenue growth momentum.
TTM EPS declined 15.4% YoY, raising earnings sustainability concerns.
Premium valuation at P/E 54.00x limits margin of safety for investors.
High payout ratio 56.18% TTM constrains reinvestment capacity for growth.
Stock price flat 0% over 52 weeks despite positive fundamentals signals weakness.
Flip Conditions.
Valuation risk. a P/E above 73 (~1.6× the sector multiple of 45.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 17% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.51%.
Dr. Lal Path Labs Ltd. peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Dr. Lal Path Labs Ltd. is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Dr. Lal Path Labs Ltd. chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Dr. Lal Path Labs Ltd. — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Dr. Lal Path Labs Ltd. delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Dr. Lal Path Labs Ltd. over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Dr. Lal Path Labs Ltd. stood at 25.8% of traded volume, against a 20-day average of 57.1%.
Dr Lal Path Labs announcements: results, concalls, ratings, M&A.
Filings Dr Lal Path Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Dr Lal Path Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 163 documents below.
Shareholders meeting
Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 25, 2026. Further, the company…
Shareholders meeting
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Proceedings of Annual General Meeting held on July 25, 2026
Copy of Newspaper Publication
Dr. Lal Path Labs Ltd. has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Dr. Lal Path Labs Ltd. has informed the Exchange about Link of Recording
Investor Presentation
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
Investor decks & rating reports.
Dr Lal Path Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Dr Lal Path Labs has declared, sequenced by announce and record date.
Dr Lal Path Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Dr Lal Path Labs insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Dr Lal Path Labs as reported to SEBI — buying and selling signals from the people who know the business best.
Dr Lal Path Labs insider activity below tracks 45 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Dr. Lal PathLabs Employees Welfare Trust | Insider | 30 Apr 2026 | buy | +82.8 K | ₹9.44 Cr. | ₹1,141.20 |
| Rahul Sharma | Insider | 30 Mar 2026 | buy | +1.0 K | ₹13.03 L | ₹1,302.70 |
About Dr. Lal Path Labs Ltd.: business, sector, key facts.
What Dr. Lal Path Labs Ltd. does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Dr. Lal Path Labs Ltd. operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: LALPATHLAB, BSE: 539524.
Dr. Lal PathLabs Limited is a prominent player in the Indian diagnostic industry, specializing in a comprehensive range of pathological investigations. Founded in 1949 and headquartered in Gurugram, India, the company operates a network of laboratories across the country and internationally, providing a wide array of diagnostic services to both individuals and healthcare institutions. Their services cater to a broad spectrum of medical needs, contributing significantly to disease diagnosis and treatment planning.
The core business of Dr. Lal PathLabs revolves around conducting a diverse range of pathological tests. Their expertise spans several key areas of laboratory medicine, including biochemistry, hematology (the study of blood), histopathology (the examination of tissues), microbiology (the study of microorganisms), electrophoresis (separation of molecules based on size and charge), immunochemistry (the study of chemical reactions involving antibodies), immunology (the study of the immune system), virology (the study of viruses), and cytology (the study of cells). This extensive coverage ensures they can handle a wide array of diagnostic requirements.
Beyond the core diagnostic offerings, Dr. Lal PathLabs also provides radiological investigations, expanding the scope of their services to include imaging techniques. This integrated approach offers healthcare providers a more complete diagnostic picture, potentially improving patient care and treatment efficacy. The company's commitment to quality and comprehensive service delivery is a key factor in their market success.
Further demonstrating a commitment to the medical field beyond direct patient services, Dr. Lal PathLabs also engages in phlebotomist training programs. This initiative addresses the need for skilled phlebotomists, who are essential for accurate and efficient sample collection, thereby contributing to the overall quality of their diagnostic services and supporting the broader healthcare system. This diversification strengthens their position within the healthcare ecosystem.
In summary, Dr. Lal PathLabs Limited is a large-scale diagnostic services provider, offering a vast menu of laboratory investigations and contributing to both clinical practice and the training of essential medical personnel. Their established presence and diverse service portfolio highlight their significant role in the Indian and international healthcare landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Health X Platform (HEALTHX) Share PricePeer
- Krsnaa Diagnostics (KRSNAA) Share PricePeer
- Metropolis Healthcare (METROPOLIS) Share PricePeer
- Suraksha Diagnostic (SURAKSHA) Share PricePeer
- Thyrocare Technologies (THYROCARE) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Dr. Lal Path Labs Ltd. (LALPATHLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Dr. Lal Path Labs Ltd. (LALPATHLAB)?
The current share price of Dr. Lal Path Labs Ltd. (LALPATHLAB) is ₹1,809. Today, the stock has declined by ₹18.20 (1.00%), trading in a range of ₹1,809 to ₹1,834.2. The stock opened at ₹1,827.2 with a trading volume of 46,295 shares.
02Is Dr. Lal Path Labs Ltd. stock a good investment for long-term?
Dr. Lal Path Labs Ltd. can be considered for long-term investment based on several factors. The company has a market capitalization of ₹30,607.3 crores, P/E ratio of 56.46, ROE of 22.30%, and ROCE of 28.00%. The dividend yield stands at 1.01%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Dr. Lal Path Labs Ltd. stock?
The 52-week high price of Dr. Lal Path Labs Ltd. (LALPATHLAB) is ₹3,540, while the 52-week low is ₹1,272.6. Currently trading at ₹1,809, the stock is 23.7% away from its 52-week low and 48.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Dr. Lal Path Labs Ltd. stock at the current price?
Whether to buy Dr. Lal Path Labs Ltd. stock at ₹1,809 depends on multiple factors. The stock is currently trading with a P/E ratio of 56.46 and P/B ratio of 12.20. Today's performance shows a loss of 1.00%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Dr. Lal Path Labs Ltd. and when is the next dividend?
Dr. Lal Path Labs Ltd. offers a dividend yield of 1.01%, which means for every ₹100 invested at the current price of ₹1,809, you can expect to receive approximately ₹1.01 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd.'s key financial metrics include: P/E Ratio: 56.46, P/B Ratio: 12.20, ROE: 22.30%, ROCE: 28.00%, Dividend Yield: 1.01%, EPS: ₹30.26, Book Value: ₹150.15, and Debt-to-Equity: 0.08. The company's market cap stands at ₹30,607.3 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Dr. Lal Path Labs Ltd. stock performing today in the market?
Dr. Lal Path Labs Ltd. stock opened at ₹1,827.2 and is currently trading at ₹1,809, showing a decline of ₹18.20 (1.00%). The intraday high is ₹1,834.2 and low is ₹1,809. The trading volume stands at 46,295 shares, indicating moderate market participation today.
08What is the P/E ratio of Dr. Lal Path Labs Ltd. and what does it indicate?
Dr. Lal Path Labs Ltd. has a Price-to-Earnings (P/E) ratio of 56.46, which means investors are willing to pay ₹56.46 for every ₹1 of earnings. With an EPS of ₹30.26, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Dr. Lal Path Labs Ltd. (LALPATHLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.